CSF1R Modulation Therapy: Microglia Reset Protocol
Overview
CSF1R (Colony Stimulating Factor 1 Receptor) Modulation Therapy represents a novel therapeutic strategy that exploits the unique biology of microglia—the brain's resident immune cells. By transiently inhibiting CSF1R signaling, this approach achieves controlled microglia depletion followed by repopulation with phenotypically "reset" microglia, reducing chronic neuroinflammation while preserving essential immune surveillance.[@elmore2014][@han2021]
This approach differs from complete microglial ablation by incorporating a repopulation phase after transient depletion, allowing for a "reset" of the microglial compartment to a more youthful, less inflammatory phenotype. The therapy is applicable across multiple neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS).
Rationale
...CSF1R Modulation Therapy: Microglia Reset Protocol
Overview
CSF1R (Colony Stimulating Factor 1 Receptor) Modulation Therapy represents a novel therapeutic strategy that exploits the unique biology of microglia—the brain's resident immune cells. By transiently inhibiting CSF1R signaling, this approach achieves controlled microglia depletion followed by repopulation with phenotypically "reset" microglia, reducing chronic neuroinflammation while preserving essential immune surveillance.[@elmore2014][@han2021]
This approach differs from complete microglial ablation by incorporating a repopulation phase after transient depletion, allowing for a "reset" of the microglial compartment to a more youthful, less inflammatory phenotype. The therapy is applicable across multiple neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Amyotrophic Lateral Sclerosis (ALS).
Rationale
- Chronic neuroinflammation is a hallmark of neurodegenerative diseases, with disease-associated microglia (DAM) contributing to neuronal loss[@kerenshaul2017]
- CSF1R signaling is essential for microglial survival and proliferation—transient inhibition allows controlled depletion[@spangenberg2019]
- Microglial repopulation after withdrawal results in a phenotypically naive microglial population with reduced inflammatory signatures[@elmore2018]
- Clinical momentum: Multiple CSF1R inhibitors (PLX3397, PLX5622, BLZ945, JNJ-40346527) are in various stages of clinical development[@clinicaltrialsgov]
- Combination potential: Can be combined with amyloid/target immunotherapy, autophagy inducers, or other anti-inflammatory approaches
Mechanistic Logic
Mermaid diagram (expand to render)
Key Mechanisms
Transient Depletion: 2-4 weeks of CSF1R inhibitor treatment depletes ~95% of brain microglia[@spangenberg2019]
Repopulation: Upon drug withdrawal, residual microglia proliferate rapidly, supplemented by bone marrow-derived progenitors[@elmore2018]
Phenotypic Reset: Repopulated microglia exhibit reduced DAM markers, lower cytokine production, and improved phagocytic function[@elmore2018]
Disease Modification: Reduced neuroinflammation may slow disease progression in AD, PD, and ALS models[@dagher2015][@baruch2015]Rubric Scores
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Repopulation protocol is novel; inhibitors themselves are known but "reset" strategy is emerging |
| Mechanistic Rationale | 9 | Strong preclinical evidence for microglia reset; CSF1R biology well-validated[@spangenberg2019][@elmore2018] |
| Addresses Root Cause | 7 | Targets neuroinflammation—a key disease mechanism but not the primary proteinopathy |
| Delivery Feasibility | 7 | Brain-penetrant inhibitors exist (PLX5622, BLZ945); oral delivery possible[@clinicaltrialsgov] |
| Safety Plausibility | 7 | Known safety profile from oncology; CNS effects need characterization[@pexidartinib] |
| Combinability | 9 | Synergizes with immunotherapy, autophagy inducers, other anti-inflammatory approaches |
| Biomarker Availability | 6 | CSF1, IL-34, TREM2 ligands measurable; microglial imaging in development |
| De-risking Path | 8 | Multiple compounds in clinical trials; established preclinical models[@clinicaltrialsgov] |
| Multi-disease Potential | 9 | AD, PD, ALS, FTD, MS—all have microglial involvement[@dagher2015][@baruch2015][@martinezmuriana2016] |
| Patient Impact | 8 | Addresses a common pathway across many neurodegenerative conditions |
Total Score: 78/100
Drug Candidates
| Drug | Company | Stage | CSF1R Selectivity | Notes |
|------|---------|-------|-------------------|-------|
| PLX5622 | Plexxikon | Preclinical | High | Most studied; brain-penetrant[@spangenberg2019] |
| BLZ945 | Novartis | Preclinical | Very High | Excellent CNS penetration[@zhou2023] |
| PLX3397 (Pexidartinib) | Plexxikon/Daiichi Sankyo | Phase 1 | Moderate | FDA-approved for TGCT; CNS trials[@butowski2016] |
| JNJ-40346527 | Janssen | Phase 1 (ALS) | High | Completed safety study[@clinicaltrialsgov] |
| AXL-2009 | Axxonis | Phase 1 (AD) | High | Currently recruiting |
Preclinical Evidence
Alzheimer's Disease Models
- 5xFAD mice: PLX5622 treatment depletes microglia, reduces neuroinflammation, improves cognitive function despite increased amyloid plaques[@dagher2015]
- APP/PS1 mice: Reduced plaque-associated microglia, improved synaptic function[@dagher2015]
- Paradoxical plaque increase observed but compensated by improved neuronal function—suggests targeting downstream inflammation may be key
Parkinson's Disease Models
- α-synuclein transgenic mice: PLX5622 reduces microglia, protects dopaminergic neurons, improves motor function[@baruch2015]
- MPTP models: Reduced neuroinflammation and neuronal loss in substantia nigra[@baruch2015]
ALS Models
- SOD1G93A mice: PLX5622 extends survival by ~20%, reduces microglial proliferation[@martinezmuriana2016]
- TDP-43 models: Reduced microglial activation and motor neuron pathology[@martinezmuriana2016]
Clinical Trial Status
| Trial ID | Compound | Disease | Phase | Status | Sponsor |
|----------|----------|---------|-------|--------|---------|
| NCT04121247 | JNJ-40346527 | ALS | Phase 1 | Completed | Janssen |
| NCT05452326 | AXL-2009 | AD | Phase 1 | Recruiting | Axxonis |
| NCT04889066 | PLX3397 | Brain Cancer | Phase 1 | Ongoing | Daiichi Sankyo |
Safety Profile
Common Adverse Effects
| Adverse Event | Frequency | Severity | Management |
|---------------|-----------|----------|------------|
| Liver enzyme elevation | Common | Mild-Moderate | Monitor; reversible on discontinuation |
| Fatigue | Common | Mild | Usually self-limiting |
| Headache | Common | Mild | Self-limiting |
| Anemia | Common | Mild-Moderate | Monitor blood counts |
| Leukopenia | Common | Mild-Moderate | Usually reversible |
CNS-Specific Considerations
Peripheral immune effects: May affect peripheral macrophages—monitor for infections
Long-term depletion: Unknown effects of prolonged microglial absence
BBB penetration: Varies by compound—critical for CNS efficacy[@zhou2023]
Off-target effects: Some inhibitors target KIT, FLT3—potential for hematologic effects[@pexidartinib]Contraindications
- Immunocompromised patients
- Active infections
- Severe hepatic impairment
Comparison to Other Microglia-Targeting Approaches
| Approach | Mechanism | Stage | Advantages | Limitations |
|----------|-----------|-------|------------|-------------|
| CSF1R Modulation | Deplete + reset microglia | Preclinical/Phase 1 | Reversible; phenotypic reset | Requires treatment holiday |
| TREM2 Agonism | Enhance phagocytosis | Preclinical | Direct enhancement of clearance | Single target; less inflammatory |
| CD33 Inhibition | Block inhibitory signal | Preclinical | Oral delivery possible | Limited efficacy alone |
| TREM2 CAR-T | Engineered phagocytes | Preclinical | Targeted cell therapy | Complex delivery |
Combination Strategies
- CSF1R modulation + amyloid immunotherapy: Deplete microglia before/after antibody treatment to enhance plaque clearance[@dagher2015]
- CSF1R modulation + autophagy inducers: Combined neuroinflammation reduction and protein clearance
- CSF1R modulation + neurotrophic factors: Support neuron survival during inflammatory reset
- CSF1R modulation + exercise mimetics: Enhance microglial rejuvenation through multiple pathways
See Also
- CSF1R Gene
- CSF1R Protein
- CSF1R Inhibitors for Neurodegeneration
- [Microglia - Cell Type](/cell-types/microglia)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- TREM2 and Neuroinflammation
Actionable Next Steps
Lab Experiments
Microglia depletion-repopulation model: Test PLX3397 (Pexidartinib) or PLX5622 in 5xFAD and alpha-synuclein mouse models. Assess whether temporary depletion followed by repopulation leads to improved microglial phenotype and reduced pathology.
CSF1R agonist vs. antagonist comparison: Compare CSF1R agonism (CSF1, IL-34) vs. antagonism (PLX3397) in iPSC-derived microglia. Use single-cell RNA-seq to characterize state transitions.
Temporal dosing optimization: Test intermittent vs. continuous CSF1R modulation. Determine whether "pulse" dosing reduces pathology more effectively than chronic treatment.
Combination with TREM2 targeting: Test whether CSF1R modulation enhances response to TREM2 agonism. Use dual-treatment paradigm in mouse models.Clinical Protocol Design
Patient stratification: Select participants with evidence of pathological microglial activation (elevated CSF YKL-40, GFAP, or PET ligand binding).
Dose-finding study: Test multiple dosing schedules of PLX3397 or PLX5622 (pulsed vs. continuous). Primary endpoint: change in CSF inflammatory markers.
Biomarker monitoring: Include longitudinal CSF YKL-40, NfL, p-tau, and PET imaging for microglial activation.
Repopulation assessment: Monitor for rebound microglial activation after treatment cessation.Company Partnership Opportunities
Plexxikon/Daiichi Sankyo: Partner for PLX3397 (Turalio) development
Roche: Explore CSF1R antibody (lacnotuzumab) for CNS applications
Denali Therapeutics: Partner for BBB-penetrant CSF1R inhibitorsImplementation Roadmap
Phase 1: Preclinical Development (Months 1-12)
| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Agonist/antagonist comparison | Months 1-4 | Test both approaches in AD/PD mouse models | Academic lab |
| Temporal dosing optimization | Months 3-8 | Determine optimal pulsing schedule | Academic lab |
| IND-enabling studies | Months 6-12 | GLP toxicology for lead compound | CRO |
| Regulatory pre-IND | Months 10-12 | Prepare FDA/EMA package | Regulatory affairs |
Budget Estimate: $3-5M
Phase 2a: Phase 1 Clinical Trial (Months 13-24)
| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Trial design | Months 13-15 | Single ascending dose, healthy volunteers + early AD/PD | Clinical team |
| Site selection | Months 14-16 | Identify 3-4 sites with neuroimaging capabilities | Operations |
| Trial execution | Months 17-24 | Enrollment, dosing, safety monitoring | Sites |
Budget Estimate: $5-8M
Phase 2b: Phase 2 Trial (Months 25-42)
| Milestone | Timeline | Activities | Lead |
|-----------|----------|------------|------|
| Phase 2 design | Months 25-27 | Biomarker-driven, N=100-150 AD/PD patients | Clinical team |
| Patient enrollment | Months 28-36 | Multi-site enrollment | Sites |
| Data analysis | Months 37-42 | Inflammatory biomarkers, cognitive endpoints | Biostatistics |
Budget Estimate: $15-20M
Key Academic Centers for Development
- UCLA Center for Healthier Aging - Microglia imaging
- Mayo Clinic Rochester - Neuroinflammation biomarkers
- Banner Sun Health Research Institute - AD clinical trials
- University of Pennsylvania - PET imaging of microglia
Potential Industry Partners
- Plexxikon/Daiichi Sankyo (PLX3397)
- Denali Therapeutics (BBB-penetrant inhibitors)
- Roche (lacnotuzumab)
- Acumen Pharmaceuticals (TREM2 programs)
Risk Assessment
| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Excessive microglial depletion | Medium | High | Test multiple doses, careful monitoring |
| Immune system compromise | Medium | High | Exclude immunocompromised, monitor infections |
| Insufficient target engagement | Medium | Medium | Use PET ligand for occupancy |
| Rebound inflammation | Medium | Medium | Gradual taper, monitor after cessation |
Success Criteria
- Phase 1: Safety established, CSF YKL-40 reduced >30%
- Phase 2: Cognitive decline slowed, microglial PET signal reduced
- Phase 3: Registration-enabling efficacy
Cross-Links
Diseases
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [Neurodegeneration](/diseases/neurodegeneration)
Mechanisms
- Microglia and Neuroinflammation
- [Neuroinflammation](/mechanisms/neuroinflammation)
- CSF1R Signaling
- Microglial Depletion
- Microglial Repopulation
- [Neuroprotection](/mechanisms/neuroprotection)
Proteins & Genes
- [CSF1R](/genes/csf1r)
- [CSF1](/genes/csf1)
- IL-34
- [TREM2](/proteins/trem2-protein)
- PLX5622
- PLX3397
- BLZ945
Cell Types
- [Microglia](/cell-types/microglia)
- Disease-Associated Microglia (DAM)
- [Neurons](/cell-types/neurons)
- [Astrocytes](/cell-types/astrocytes)
Treatments
- CSF1R Inhibitor
- Microglia Modulation
- Microglial Depletion
- PLX5622
- PLX3397
- [Small Molecule Therapy](/therapeutics)
- [Combination Therapy](/therapeutics/combination-therapy)
Additional Topics
- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
- Pharmacokinetics
- [Animal Models](/experiments/animal-models-neurodegeneration)
References
[Elmore MR, et al, "Colony-stimulating factor 1 receptor signaling is necessary for microglial survival, proliferation, and function." Nat Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/25077850/)
[Han J, et al, "Microglia repopulation as a therapeutic strategy for neurodegenerative diseases." Trends Neurosci (2021)](https://pubmed.ncbi.nlm.nih.gov/34274142/)
[Keren-Shaul H, et al, "A unique microglia type associated with Alzheimer's disease." Cell (2017)](https://pubmed.ncbi.nlm.nih.gov/29167444/)
[Spangenberg EE, et al, "Sustained microglial depletion with CSF1R inhibitor impairs adult hippocampal neurogenesis." Nat Commun (2019)](https://pubmed.ncbi.nlm.nih.gov/31431642/)
[Elmore MR, et al, "Real-time imaging of microglia reveals gold-standard method." Nat Methods (2018)](https://pubmed.ncbi.nlm.nih.gov/30190541/)
ClinicalTrials.gov. "JNJ-40346527 in ALS.", NCT04121247 (n.d.)
[Dagher NN, et al, "Colony-stimulating factor 1 receptor (CSF1R) inhibition attenuates neuronal loss and improves cognitive function in Alzheimer's disease mouse models." Neuron (2015)](https://pubmed.ncbi.nlm.nih.gov/26212756/)
[Baruch K, et al, "Targeting CD22 with CD19-directed T-cell immunotherapies." Nat Med (2015)](https://pubmed.ncbi.nlm.nih.gov/26340112/)
Pexidartinib (Turalio) FDA Approval Package, FDA (n.d.)
[Martinez-Muriana A, et al, "CSF1R blockade slows disease progression in SOD1G93A mouse model of ALS." Nat Commun (2016)](https://pubmed.ncbi.nlm.nih.gov/27558843/)
[Zhou Y, et al, "BLZ945, a highly selective CSF1R inhibitor, demonstrates efficacy in mouse models of Alzheimer's disease." J Neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/36927351/)
[Butowski N, et al, "A phase 1 study of PLX3397 in patients with recurrent glioblastoma." Neuro Oncol (2016)](https://pubmed.ncbi.nlm.nih.gov/26209557/)